fashion -WSS

fashion

author：comprehensive 2025-09-06 02:06:45 - browse：79469

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： The problem with charging patients to message their doctors

hotspot

leisure time

WSS

House GOP plan to stem drug shortages differs from Democrats’

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

How to bring more disabled researchers into academia

entertainment

fashion

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Teacher posts viral 'school supply rant' with advice for parents

Medicare details structure of new drug price negotiation program

CDC marks new Covid

Medical leaders decry Supreme Court decision on affirmative action

With psoriasis trial ahead, Alumis raises $259 million

In Memoriam: Notable people who died in 2023

First medicine developed to treat MASH expected to be approved soon

As demand for Covid shots wanes, Moderna seeks its next success

The drug industry has found itself all alone in Washington

focus

Russian and Belarusian players banned from a women's tennis tournament in Prague

NEJM study link tiny plastics in blood vessels to heart problems

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

Judge orders hearing on Trump's motion to disqualify Fulton County DA

What AstraZeneca

Amylyx ALS drug fails large clinical trial

hotspot

knowledge

leisure time

leisure time